Bristol-Myers Squibb (BMS) has suspended a clinical trial of an experimental hepatitis C treatment after one study volunteer experienced heart failure, the Wall Street Journal reports. The Phase II study of the drug, an NS5B inhibitor dubbed BMS-986094 and formerly known as INX-189, will remain halted until the 30 participants who have thus far been enrolled in the study can be tested for heart abnormalities. “At this point, a path forward for the development of this compound is unclear,” a BMS spokesperson added.

To read the Wall Street Journal article, click here.